Y-Mabs Therapeutics Gross Profit

As of the most recent data (June 2025), YMAB shows a gross profit of $72M. That compares with $77M in the prior-year period — down 6.3% year over year. That is below the Healthcare sector average of $66B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, YMAB's gross profit is now $72M (was $77M) — a 6.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Y-Mabs Therapeutics is outperforming or lagging.

The Healthcare sector average gross profit is about $66B. Y-Mabs Therapeutics is at $72M, which is lower that average. That is roughly 99.9% below the sector mean. Use the comparison chart on this page to see how YMAB stacks up against individual peers as well.

Tracking YMAB's gross profit over time shows whether Y-Mabs Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $72M That compares with $77M in the prior-year period — down 6.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Y-Mabs Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $72M) with ownership activity and broader fundamentals.